Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Expanded Access Program Intended to Provide Treatment With Ecopipam (EBS-101) to Children, Adolescents, and Adults in the U.S. With Tourette's Disorder

NCT07093541 is registered in ClinicalTrials.gov with Emalex Biosciences Inc. as lead sponsor.

NCT NCT07093541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07093541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Expanded Access Program Intended to Provide Treatment With Ecopipam (EBS-101) to Children, Adolescents, and Adults in the U.S. With Tourette's Disorder
Lead sponsor
Emalex Biosciences Inc.
Phase
Expanded access
Overall status
Temporarily not available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

tourette disorder, tourettes disorder